ArticleVaccines2021
Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- Enolase AmEno15, a Promising Candidate for Understanding the Infectious Process ofInternational journal of molecular sciences · 2025Article
- Molecular Identification and Bioinformatics Analysis ofPathogens (Basel, Switzerland) · 2024Article
- Integrated Information for Pathogenicity and Treatment of Spiroplasma.Current microbiology · 2024Review
- Haemotrophic Mycoplasmas Infecting Pigs: A Review of the Current Knowledge.Microorganisms · 2024Review
- Screening of immunogenic proteins and evaluation of vaccine candidates against Mycoplasma synoviae.NPJ vaccines · 2023Article
- An alternative vaccine target for bovine Anaplasmosis based on enolase, a moonlighting protein.Frontiers in veterinary science · 2023Article
- Evaluation of the protective efficacy of six major immunogenic proteins ofFrontiers in veterinary science · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant protein technology has emerged as an excellent option for vaccine development. However, prior to our study, the immune induction ability of recombinant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.